-+ 0.00%
-+ 0.00%
-+ 0.00%

SENTI BIO ANNOUNCES UPDATED SENTI-202 CLINICAL DATA FROM ONGOING PHASE 1 TRIAL IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS, DEMONSTRATING DEEP, MRD NEGATIVE, DURABLE COMPLETE REMISSIONS AND A FAVORABLE SAFETY PROFILE

路透·12/09/2025 12:00:02

登录查看新闻详情